Phase 2 results of the Nash trial and new Partner Deal still on...

Phase 2 results of the Nash trial and new Partner Deal still on track to be released this quarter according to Gary in this new interview ..STRONG BUY before the news hit the wire
https://unauthorised investment advice/health/health-kick-podcast-developing-drugs-fighting-fibrosis-and-squeezing-squishometers/

Meanwhile, Pharmaxis (ASXXS) has developed a treatment for cystic fibrosis called Bronchitol, which is approved in Europe and subject to US approval.The company is also eyeing treatments for a common liver disease called NASH – non alcoholic steatohepatitis, or ‘fatty liver disease’ – as well as diabetic retinopathy and the fatal lung disease idiopathic pulmonary fibrosis.So tune in to hear the pair discuss developing drugs, fighting fibrosis and squeezing squishometers